During the the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center presented the results from a retrospective analysis on the safety of nivolumab in 4 ongoing phase I-III studies in patients with melanoma. This monoclonal antibody was found to be an important therapeutic agent and was able to improve the survival rates of patients with melanoma.
Conferences
Frontline BRAF/MEK Combo Improves Survival in Melanoma
Combination therapy with the MEK inhibitor trametinib (Mekinist) and the BRAF inhibitor dabrafenib (Tafinlar) reduced the risk of death by 29% in patients with BRAF-mutant advanced melanoma, according to the final results from the COMBI-d phase III trial, which were presented at the 2015 ASCO Annual Meeting and simultaneously published in The Lancet.
Novel Data On PV-10 For Melanoma Treatment Presented At ASCO
New findings on PV-10, an investigational intra-lesional therapy for melanoma, were presented during the American Society of Clinical Oncology’s Annual Meeting on May 31, 2015, Chicago, Illinois, USA. The presentation entitled “A Changing Topography: The Role of Intralesional Therapy in Melanoma” was presented by Dr. Sanjiv Agarwala, from St. Luke’s Cancer Center in Bethlehem and Temple University School of Medicine in Pennsylvania, USA.
Updated Data on Targeted Therapy Combination Confirm Benefit in Melanoma
The combination of the BRAF inhibitor vemurafenib and the investigational MEK inhibitor cobimetinib continues to provide clinical benefit for untreated patients with BRAF-mutated metastatic melanoma, according to updated results of the phase III coBRIM trial (abstract 9006) presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2, in Chicago.